Evaluation of an esophagoprotector adhesive properties based on hyaluronic acid and chondroitin sulfate to the pharyngeal and laryngopharyngeal mucosa
DOI: 10.32364/2225-2282-2025-10-1
Evaluation of an esophagoprotector adhesive properties based on hyaluronic acid and chondroitin sulfate to the pharyngeal and laryngopharyngeal mucosa
L.A. Dzhauktsian, M.V. Svistushkin, L.V. Selezneva, M.V. Yurazh, E.T. Ikaeva, V.M. Svistushkin
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow
Background: a group of medical devices, esophagoprotectors, which provide protection for the esophageal mucosa and are designed for the pathogenetic therapy of gastroesophageal reflux disease (GERD), is currently being actively studied.
Aim: to assess the degree of adhesion of the esophagoprotector (a combination of hyaluronic acid (HA) and chondroitin sulfate (CS)) to the pharyngeal and laryngopharyngeal mucosa, as well as to determine the prospects for its use in the treatment of laryngopharyngeal reflux (LFR).
Patients and Methods: the study involved 30 healthy volunteers, divided into two groups (n=15 in each): the main group, in which volunteers received 10 ml of the esophagoprotector solution (HA + CS) containing 1 ml of blue water-soluble food dye, and the control group, in which volunteers received a solution of blue water-soluble food dye without active components. The degree of adhesion was assessed on the original scale from 0 to 3 points based on videolaryngoscopy 15, 30, 60, 90, and 120 minutes after esophagoprotector application.
Results: the main group demonstrated statistically significantly higher adhesion compared to the control at all time points except 120 minutes (p <0.001). The maximum adhesion was observed at the 15th minute (average score 3.0), then gradually decreased to 0.2 by the 120th minute. There was no adhesion in the control group (median=0).
Conclusion: the combination of HA and CS has a significant adhesive ability to the pharyngeal and laryngopharyngeal mucosa, maintaining the effect for up to 90 minutes. The results obtained substantiate the efficacy of esophagoprotectors in the treatment of laryngopharyngeal reflux.
Keywords: laryngopharyngeal reflux, hyaluronic acid, chondroitin sulfate, degree of adhesion, gastroesophageal reflux disease, esophagoprotection.
For citation: Dzhauktsian L.A., Svistushkin M.V., Selezneva L.V., Yurazh M.V., Ikaeva E.T., Svistushkin V.M. Evaluation of an esophagoprotector adhesive properties based on hyaluronic acid and chondroitin sulfate to the pharyngeal and laryngopharyngeal mucosa. RMJ. 2025;10:4-8. DOI: 10.32364/2225-2282-2025-10-1
2. Радциг Е.Ю., Константинов Д.И. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни: взгляд оториноларинголога. Терапевтический архив. 2021;93(4):521–525. [Radtsig E.Yu., Konstantinov D.I. Extraesophageal signs of gastroesophageal reflux disease: otorhinolaryngologist’s view. Terapevticheskii Arkhiv (Ter. Arkh). 2021;93(4):521–525 (in Russ.)]. DOI: 10.26442/00403660.2021.04.200814
3. Lechien J.R., Saussez S., Schindler A. et al. Symptoms and signs outcomes of laryngopharyngeal reflux treatment: a critical systematic review and meta-analysis. Laryngoscope. 2019;129(5):1174–1187. DOI: 10.1002/lary.27591
4. Старостина С.В., Махов В.М., Сторонова О.А. и др. Возможности 24-часовой pН-импедансометрии пищевода в диагностике ГЭРБ-ассоциированных заболеваний гортани. Медицинский совет. 2020;(16):62–72. [Starostina S.V., Makhov V.M., Storonova O.A. et al. Сapabilitу of 24-hour esophageal pH-impedance monitoring in the diagnosis of GERD-associated laryngeal diseases. Medical Council. 2020;(16):62–72 (in Russ.)]. DOI: 10.21518/2079-701X-2020-16-62-72
5. Лаптева И.В., Федорин М.М., Нестерова К.И. и др. Возможности терапии эзофагопротектором в ведении больного ГЭРБ с внепищеводными проявлениями. РМЖ. Медицинское обозрение. 2022;6(5):237–243. [Lapteva I.V., Fedorin M.M., Nesterova K.I. et al. Therapy with esophageal protector in the management of GERD with extraesophageal symptoms. Russian Medical Inquiry. 2022;6(5):237–243 (in Russ.)]. DOI: 10.32364/2587-6821-2022-6-5-237-243
6. Pendleton H., Ahlner-Elmqvist M., Olsson R. et al. Posterior laryngitis: a disease with different aetiologies affecting health-related quality of life: a prospective case-control study. BMC Ear Nose Throat Disord. 2013;13(1):11. DOI: 10.1186/1472-6815-13-11
7. Han H., Lyu Q., Zhao J. Laryngopharyngeal Reflux in Hypertrophic Laryngeal Diseases. Ear Nose Throat J. 2022;101(4):NP158–NP163. DOI: 10.1177/0145561320953232
8. Massawe W.A., Nkya A., Abraham Z.S. et al. Laryngopharyngeal reflux disease, prevalence and clinical characteristics in ENT department of a tertiary hospital Tanzania. World J Otorhinolaryngol Head Neck Surg. 2020;7(1):28–33. DOI: 10.1016/j.wjorl.2020.04.009
9. Епанчинцева А.С. Фактор высокого гастроэзофагеального рефлюкса в развитии различных форм хронического фарингита: автореф. дис. … канд. мед. наук. М., 2010. [Epanchintseva A.S. The factor of high gastroesophageal reflux in the development of various forms of chronic pharyngitis: thesis. M.; 2010 (in Russ.)].
10. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal Definition and Classification of GERD. Am J Gastroenterol. 2006;101:1900–1920. DOI: 10.1111/j.1572 0241.2006.00630.x
11. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Шабуров Р.И. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4–11. [Maev I.V., Andreev D.N., Kucheryavyy Y.A., Shaburov R.I. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii arkhiv. (Ter Arch.). 2019;91(8):4–11 (in Russ.)]. DOI: 10.26442/00403660.2019.08.000387
12. Эмбутниекс Ю.В., Валитова Э.Р., Бордин Д.С. Новый подход к лечению гастроэзофагеальной рефлюксной болезни: защита слизистой оболочки пищевода. Эффектив-ная фармакотерапия. 2019;15(18):16–22. [Embutnieks Yu.V., Valitova E.R., Bordin D.S. A new approach to the treatment of gastroesophageal reflux disease: protection of the mucous membrane of the esophagus. Effective pharmacotherapy. 2019;15(18):16–22 (in Russ.)]. DOI: 10.33978/2307-3586-2019-15-18-16-22
13. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2016;273(11):3795–3801. DOI: 10.1007/s00405-016-4142-y
14. Qadeer M.A., Phillips C.O., Lopez A.R. et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646–2654. DOI: 10.1111/j.1572-0241.2006.00844.x
15. Shaheen N.J., Crockett S.D., Bright S.D. et al. Randomised clinical trial: high-dose acid suppression for chronic cough — a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):225–234. DOI: 10.1111/j.1365-2036.2010.04511.x
16. Savarino E., Zentilin P., Marabotto E. et al. Drugs for improving esophageal mucosa defense: where are we now and where are we going? Ann Gastroenterol. 2017;30(6):585–591. DOI: 10.20524/aog.2017.0187
17. Бордин Д.С., Андреев Д.Н., Маев И.В. Эффективность эзофагопротекции в комплексном лечении эрозивной формы гастроэзофагеальной рефлюксной болезни: систе-матический обзор и метаанализ контролируемых исследований. Терапевтический архив. 2022;94(12):1407–1412. [Bordin D.S., Andreev D.N., Maev I.V. Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: a systematic review and meta-analysis of controlled trials. Terapevticheskii arkhiv. (Ter Arkh.). 2022;94(12):1407–1412 (in Russ.)]. DOI: 10.26442/00403660.2022.12.202011
18. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. и др. Эффективность эзофагопротектора в лечении пациентов с гастроэзофагеальной рефлюксной болезнью: систематический обзор. Медицинский Совет. 2022;(15):20–26. [Maev I.V., Andreev D.N., Kucheryavyy Yu.A. et al. Efficacy of an esophageal mucosal protectant in the treatment of patients with gastroesophageal reflux disease: systematic review. Medical Council. 2022;16(15):20–26 (in Russ.)]. DOI: 10.21518/2079-701X-2022-16-15-20-26
19. Palmieri B., Corbascio D., Capone S., Lodi D. Preliminary clinical experience with a new natural compound in the treatment of esophagitis and gastritis: symptomatic effect. Trends Med. 2009;9(4):219–225.
20. Palmieri B., Merighi A., Corbascio D. et al. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17(24):3272–3278. PMID: 24379055.
21. Savarino V., Pace F., Scarpignato C., Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease — efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–642. DOI: 10.1111/apt.13914
22. Бакулина Н.В., Тихонов C.В., Топалова Ю.Г. и др. Эзофагопротективная терапия у пациентов с эрозивным эзофагитом. Терапевтический архив. 2022;94(8):985–991. [Bakulina N.V., Tikhonov S.V., Topalova Yu.G. et al. Esophagoprotective therapy in patients with erosive esophagitis. Terapevticheskii Arkhiv (Ter Arkh.). 2022;94(8):985–991 (in Russ.)]. DOI: 10.26442/00403660.2022.08.201828
23. Кучерявый Ю.А., Мовтаева П.Р., Зайратьянц О.В. и др. Эффективность эзофагопротекции при коротких периодах отмены поддерживающей терапии ингибиторами протонной помпы у пациентов с пищеводом Баррета. Consilium Medicum. 2021;23(5):417–421. [Kucheryavy Yu.A., Movtaeva P.R., Zairatyants O.V. et al. The effectiveness of esophagoprotection during short periods of discontinuation of maintenance therapy with proton pump inhibitors in patients with Barrett’s esophagus. Consilium Medicum. 2021;23(5):417–421 (in Russ.)]. DOI: 10.26442/20751753.2021.5.200895
24. Chmielecka-Rutkowska J., Tomasik B., Pietruszewska W. Rola doustnego preparatukwasu hialuronowego i siarczanu chondroityny w leczeniu pacjentówz refluksem krtaniowogardłowym. Otolaryngol Pol. 2019;73(6):38–49. DOI: 10.5604/01.3001.0013.5776
25. Gąsiorowska A. Protection and regeneration of esophageal, pharyngeal, and laryngeal mucosa as a major element in therapy of patients with esophageal and extraesophageal reflux symptoms. Otolaryngol Pol. 2020;74(4):40–45. DOI: 10.5604/01.3001.0014.3614
26. Кучерявый Ю.А., Андреев Д.Н., Еремина Е.Ю. и др. Эффективность эзофагопротектора в лечении гастроэзофагеальной рефлюксной болезни с внепищеводной симпто-матикой: результаты открытого наблюдательного многоцентрового исследования. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):38–49. [Kucheryavy Yu.A., Andreyev D.N., Eryomina E.Yu. et al. Efficacy of Esophageal Protector in Treating Gastroesophageal Reflux Disease with Extraesophageal Symptoms: A Multicenter, Open-Label, Observational Study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):38–49 (in Russ.)]. DOI: 10.22416/1382-4376-2022-32-4-38-49
This work is licensed under a Creative Commons «Attribution» 4.0 License.
